Home / Global / Cancer patients demand regulation of the Cancer law while they continue to die

Cancer patients demand regulation of the Cancer law while they continue to die

Patients with cancer organized in the Association of Cancer Patients and Family members (APACFA) and waited today the management report of the chairman Mario Abdo Benitez and reiterated the need to already have the regulations of the law of the cancer.

“We are waiting more than 60 days ago, we need the regulation of the law, every day counts, every day more patients die, ” they said.

Law 6266/18 on comprehensive care for people with cancer was enacted in March this year and patients continue to await regulations for compliance with the regulations.

With the entry into force of the law, oncology patients will be protected for comprehensive care in the diagnosis, treatment and follow-up of each case and the provision of what is necessary for these stages by the state.

Article 17 states that the MSP will be responsible for drawing up a national list of antineoplastic drugs and those complementary to the treatment, follow-up and palliative care for people with cancer, as part of the National List of essential drugs.

“Based on this list and the scientific evidence, it will establish diagnostic and treatment protocols, specifying the antineoplastic drugs that will be used in the different therapeutic schemes, in the National Health System, ” the regulation adds.

Both diagnostic and treatment protocols, as well as the National antineoplastic Drug List and those complementary to treatment, follow-up and palliative care, will be evaluated and updated periodically, following the recommendations of the “National Advisory Commission for Comprehensive Cancer Care”.

“The State shall ensure the timely access to diagnostic services and cancer treatment in the National Health System, according to the technical standards, protocols, and the List National Drug Antineoplastic and those complementary to the treatment, monitoring and palliative care, established by the Ministry of Public Health and Social Welfare (MSPBS)”, contained in Article 18 of the law.

Rate this post

Check Also

European Commission approves talazoparib for metastatic or locally advanced breast cancer with BRCA mutation

The oral polyadp-ribose polymerase (PARP) inhibitor, talazoparib, has been approved by the European Commission with …

Leave a Reply

Your email address will not be published. Required fields are marked *